NRX Pharmaceuticals, Inc. Common Stock
Symbol: NRXP (NASDAQ)
3.32
▲ (0.48%) 0.016
Company Description:
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
Key Stats
- Today's Open: $3.31
- Today's High: $3.489
- Today's Low: $3.185
- Today's Volume: 284.28K
- Yesterday Close: $3.3
- Yesterday High: $3.48
- Yesterday Low: $3.2
- Yesterday Volume: 438.85K
- Last Min Volume: 662
- Last Min High: $3.323
- Last Min Low: $3.319
- Last Min VWAP: $3.32172
Company Profile
- Name: NRX Pharmaceuticals, Inc. Common Stock
- Website: https://nrxpharma.com
- Listed Date: 2021-05-25
- Location: WILMINGTON, DE
- Market Status: Active
- CIK Number: 0001719406
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $78.44M
- Round Lot: 100
- Outstanding Shares: 23.77M
- Asset Type: CS
RECENT FILINGS FOR NRXP
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-09-26 | 8-K | View |
| 2025-09-12 | 8-K | View |
| 2025-09-10 | 4 | View |
| 2025-09-10 | 4 | View |
| 2025-09-10 | 4 | View |
| 2025-09-10 | 4 | View |
| 2025-09-08 | 8-K | View |
| 2025-08-21 | SCHEDULE 13G | View |
| 2025-08-21 | 3 | View |
| 2025-08-18 | 8-K | View |
| 2025-08-18 | 424B5 | View |
| 2025-08-18 | 10-Q | View |
| 2025-08-15 | 8-K | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | NT 10-Q | View |
| 2025-06-24 | RW | View |
| 2025-06-20 | S-3 | View |
| 2025-06-09 | 8-K | View |
| 2025-05-21 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G | View |
Latest News on NRXP